Related Experiment Video
Updated: May 21, 2026
Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
Published on: September 27, 2024
In vivo imaging of oligonucleotide delivery
Fumitaka Takeshita1, Ryou-U Takahashi, Jun Onodera
1Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan.
Abstract:
RNA interference (RNAi) has rapidly become a powerful tool for drug-target discovery and therapeutics. Cancer is an important application for RNAi therapeutics, since abnormal gene regulation is thought to contribute to the pathogenesis and maintenance of the metastatic phenotype of cancer. Many oncogenic genes present enticing therapeutic target possibilities for RNAi. Small interfering RNA (siRNA) and microRNA (miRNA) are potent and specific examples of RNAi are able to silence tumor-related genes and multiple oncogenic pathways and appear to be a rational approach to inhibit tumor growth. In subsequent in vivo studies, an appropriate animal model must be developed for a better evaluation of gene-silencing effects on tumors. How to evaluate the effect of siRNA and miRNA in an in vivo therapeutic model is also important. Bioluminescence imaging is an optical imaging method that can evaluate RNAi in vivo.
Insights
RNA interference (RNAi) offers a promising therapeutic strategy for cancer by silencing oncogenic genes. Bioluminescence imaging provides an effective method for evaluating RNAi
Area of Science:
- Biotechnology
- Molecular Biology
- Oncology
Background:
- RNA interference (RNAi) is a key mechanism for gene silencing.
- Aberrant gene regulation drives cancer pathogenesis and metastasis.
- Oncogenic genes are potential targets for RNAi-based cancer therapies.
Purpose of the Study:
- To explore the application of RNA interference (RNAi) therapeutics in cancer treatment.
- To highlight the role of small interfering RNA (siRNA) and microRNA (miRNA) in silencing tumor-related genes.
- To emphasize the importance of in vivo evaluation models for RNAi therapeutics.
Main Methods:
- Utilizing small interfering RNA (siRNA) and microRNA (miRNA) to target oncogenic pathways.
- Developing appropriate animal models for in vivo studies of RNAi effects.
- Employing bioluminescence imaging for non-invasive assessment of gene-silencing efficacy in vivo.
Main Results:
- RNAi, specifically siRNA and miRNA, demonstrates potential in silencing tumor-specific genes.
- In vivo studies are crucial for validating the therapeutic effects of RNAi in cancer models.
- Bioluminescence imaging enables effective monitoring of RNAi-mediated gene silencing in living organisms.
Conclusions:
- RNAi therapeutics, including siRNA and miRNA, represent a rational approach to inhibit tumor growth.
- Effective in vivo models and imaging techniques are essential for advancing RNAi cancer therapy.
- Targeting oncogenic pathways with RNAi holds significant promise for cancer drug discovery and treatment.
